In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

mRNA Vaccines – Trials Line Up Against Coronavirus

New Technology Attracts Attention

Executive Summary

The arrival of SARS-CoV-2 has focused attention on a potential new way of making vaccines – one that promises to be quicker and cheaper than traditional methods and more reactive to novel virus outbreaks, but also one that remains to be validated.

You may also be interested in...



Finance Watch: Sana Reveals Cash Haul Of $700m In Under Two Years

Private Company Edition: The allogeneic cell therapy developer founded by former Juno execs launched in January 2019 without disclosing its initial funding. Other recent venture capital mega-rounds include $192m for Orca, $170m for C4, $118m for Shattuck and $102m for GreenLight.

Biocad To Launch Two Biosimilars In Bosnia-Herzegovina

Russia’s Biocad, with biosimilars already launched in numerous global markets, is continuing to look outward. A focus on territories in south-east Europe has seen the firm receive approvals for two biosimilars in the Balkan country Bosnia and Herzegovina.

CureVac Denies Takeover Reports As It Slates Phase I Coronavirus Vaccine Study For Early Summer

The German biotech firm has denied receiving any offer from the Trump administration in a wide-ranging conference call that also addressed recent changes at the top, its clinical timeline for a coronavirus vaccine and new funds from the European Commission to boost production.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

IV124481

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel